A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

NCT00000757 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: gp160 Vaccine (MicroGeneSys)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]